Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Ondansetron for the Prevention of Patient Self-Inflicted Lung Injury in Patients With ARDS - Pilot RCT (OSIRIS-1)

A Pilot, Randomized, Controlled Clinical Trial Evaluating Ondansetron for the Prevention of Patient Self-Inflicted Lung Injury Through Inhibition of Respiratory Drive in Patients With Acute Respiratory Distress Syndrome (OSIRIS-1)

Acute Respiratory Distress Syndrome (ARDS) is a serious condition where the lungs become inflamed, leading to severe breathing difficulties. Despite advances in medical care, ARDS remains a life-threatening illness with a high risk of death and long-term complications. One way doctors help ARDS patients is by using special ventilation techniques to protect the lungs from further damage. However, this often requires heavy sedation or even paralyzing medications, which can lead to other problems like delirium, muscle weakness, and longer hospital stays. Allowing patients to breathe on their own might offer benefits, but it also comes with risks. Many ARDS patients have a very strong urge to breathe, which can cause them to overexert their lungs, potentially leading to additional lung damage, known as patient selfinflicted lung injury (P-SILI). Our early research suggests that a medication called ondansetron, commonly used to prevent nausea, might help reduce this strong breathing drive in ARDS patients, possibly preventing further lung injury. The OSIRIS research program is designed to explore whether ondansetron can protect ARDS patients from P-SILI, ultimately improving their chances of survival and reducing long-term complications. The first part of this program, OSIRIS-1, is a small pilot study where we will test the feasibility of running a larger, more definitive trial. We will randomly assign ARDS patients to receive either ondansetron or a placebo, given intravenously four times a day, and monitor their heart rhythms closely to ensure safety. We will also track how well patients stick to the study plan and whether ondansetron helps reduce their breathing drive and lung strain. If successful, this research could lead to new ways of treating ARDS that rely less on heavy sedation, potentially improving outcomes for these critically ill patients and setting the stage for larger, more comprehensive studies in the future.

Studieöversikt

Detaljerad beskrivning

BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is a life-threatening inflammatory lung condition with high mortality and long-term morbidity. Lung-protective ventilation - targeting low tidal volumes and driving pressures - is one of the few proven interventions but often requires deep sedation and neuromuscular blockade (NMB), which are associated with delirium, ICU-acquired weakness, and prolonged ICU stays. Maintaining spontaneous breathing can offer physiological advantages but is frequently limited by excessive respiratory drive, which increases the risk of patient self-inflicted lung injury (P-SILI). Lung inflammation leading to stimulation and sensitization of pulmonary vagal afferent Cfibers could contribute to excessive respiratory effort. Stimulation of pulmonary C-fibers by serotonin increases respiratory rate in animal models through 5-HT receptors. Our previous data suggest that 3 ondansetron, a 5-HT receptor antagonist, attenuates respiratory drive and effort. We hypothesize that 3 this effect may reduce the need for sedation and paralysis, minimize P-SILI, and ultimately improve outcomes in ARDS.

OBJECTIVES: The overarching goal of the OSIRIS research program is to evaluate whether regular intravenous ondansetron can improve patient-important outcomes (survival, ventilator-free days and long term neurocognitive function) in patients with ARDS. With the OSIRIS-1 pilot study, our objective is to assess:

Feasibility:

[RQ1] What is the adherence to the study protocol? [PRIMARY] [RQ2] What is the completeness of the data collection? [RQ3] What is the recruitment rate?

Preliminary mechanistic efficacy and safety:

[RQ4] Does it decrease respiratory effort? [RQ5] Does it reduce exposure to sedatives, opioids and neuromuscular blockers? [RQ6] Is the intervention safe?

METHODS: OSIRIS-1 is a multicenter, double-blind, parallel-group, phase 2 and feasibility pilot RCT. We will enroll 76 invasively mechanically ventilated adults with moderate-to-severe ARDS (PaO :FiO2 < 200). Participants will be randomized to receive ondansetron 8 mg IV or placebo every 8 hours until liberation from invasive mechanical ventilation. Feasibility will be assessed through protocol adherence (defined as scheduled doses administered within ±2 hours), completeness of key clinical outcomes (ventilator-free days, coma/delirium-free days, 90-day survival), and site-level recruitment metrics. For preliminary efficacy, we will estimate respiratory drive using Pmus (derived from occlusion pressure, ΔPocc), measured three times daily by respiratory therapists. We will also measure P0.1, respiratory rate, and other ventilatory parameters. For safety, we will monitor the occurrence of ventricular arrhythmias, serotonin syndrome, and other serious adverse events.

IMPACT: OSIRIS-1 will provide essential data on mechanistic efficacy, safety, and feasibility to inform the design of a future large-scale trial evaluating patient-important outcomes. By targeting respiratory drive pharmacologically, we may enable safer spontaneous breathing, reduce the harms of oversedation and paralysis, and ultimately improve outcomes in ARDS.

Studietyp

Interventionell

Inskrivning (Beräknad)

76

Fas

  • Fas 2
  • Fas 3

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Quebec
      • Montreal, Quebec, Kanada, H4J 1C5
        • Hôpital du Sacré-Cœur de Montréal
        • Kontakt:
        • Huvudutredare:
          • Yiorgos Alexandros Cavayas, MD MSc

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  • Moderate-to-severe ARDS with all of the following:
  • Hypoxemic respiratory failure with PaO2:FiO2 < 200 (on IMV with PEEP ≥ 5)
  • Precipitated within 1 week of an acute condition
  • Bilateral opacities on chest radiography and computed tomography or bilateral B lines and/or consolidations on ultrasound not fully explained by effusions, atelectasis, or nodules/masses
  • Pulmonary edema not exclusively or primarily attributable to cardiogenic pulmonary edema/fluid overload
  • Hypoxemia/gas exchange abnormalities not primarily attributable to atelectasis
  • IMV initiated < 96 hours
  • Extubation not anticipated within 24 hours

Exclusion Criteria:

  • Neuromuscular disease impairing spontaneous breathing
  • Pregnancy
  • Liver cirrhosis (Child B or C) or other severe impairment of hepatic function
  • Bradycardia (baseline pulse<50/min) on screening day
  • Known long QT syndrome
  • History of sustained ventricular tachycardia
  • Active digestive / abdominal infection44
  • QTc prolongation > 470 msec in men and > 480 msec in women on screening day
  • On a medication at high risk of QT prolongation (Table 5)50
  • On two or more serotonergic medications (Table 6)51
  • Hypersensitivity / intolerance to 5-HT3 antagonists
  • Patient deemed unlikely to survive past 24 hours or being transitioned to a fully palliative philosophy of care

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Ondansetron
The first dose of intravenous ondansetron will be administered within 24 hours of randomization, every 8 hours, for duration of invasive mechanical ventilation.
Participants randomized to the ondansetron arm will receive ondansetron hydrochloride dihydrate 8 mg IV every 8 hours, administered in 10 mL of 0.9% sodium chloride in prepared syringes over 15 minutes.
Placebo-jämförare: Placebo
The first dose of intravenous placebo will be administered within 24 hours of randomization, every 8 hours, for duration of invasive mechanical ventilation.
Participants randomized to the placebo arm will receive 10 mL of 0.9% sodium chloride in prepared syringes administered over 15 minutes every 8 hours, matching the appearance, volume, and administration modalities of ondansetron to maintain blinding.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
protocol adherence
Tidsram: duration of intervention (duration of invasive mechanical ventilation)
Adherence will be measured as the proportion of scheduled doses (±2h window) administered; protocol-defined withholdings (e.g., electrophysiological disturbances) will be documented but not counted as non-adherence.
duration of intervention (duration of invasive mechanical ventilation)

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Outcome data completeness
Tidsram: 90 days
Data completeness for 90 day survival, 28 day ventilator-free days, and 14 day coma-and-delirium-free days.
90 days
Enrolment rate
Tidsram: Duration of the study
Patients enrolled by site by 12-month period
Duration of the study

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pmus
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
Pmus will be estimated by the occlusion pressure maneuvre, measured 3 times per day.
duration of the intervention (duration of invasive mechanical ventilation)
P0.1
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
P0.1 will be measured 3 times per day.
duration of the intervention (duration of invasive mechanical ventilation)
Respiratory Rate
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
Respiratory Rate will be measured 3 times per day.
duration of the intervention (duration of invasive mechanical ventilation)
Tidal volume
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
Tidal volume will be measured 3 times per day.
duration of the intervention (duration of invasive mechanical ventilation)
PaO2:FiO2 ratio
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
PaO2:FiO2 ratio will be measured 3 times per day.
duration of the intervention (duration of invasive mechanical ventilation)
Number of days of deep sedation
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
A deep sedation will be defined as a day in which a Richmond Agitation and Sedation Scale (RASS) of -4 or -5 was present for the majority of the day
duration of the intervention (duration of invasive mechanical ventilation)
Average daily oral morphine equivalent
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
All opiates received during a given day will be converted in oral morphine equivalent and summed up.
duration of the intervention (duration of invasive mechanical ventilation)
Days with NMB administration
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
Defined by having received any dose or neuromuscular blocker during a given day.
duration of the intervention (duration of invasive mechanical ventilation)
Sustained Ventricular Arrhythmia
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
Defined as ventricular tachycardia or fibrillation sustained for ≥30 seconds or requiring termination due to hemodynamic compromise in <30 seconds.
duration of the intervention (duration of invasive mechanical ventilation)
Serotonin Syndrome
Tidsram: duration of the intervention (duration of invasive mechanical ventilation)
Serotonin syndrome (ie, serotonin toxicity) is a potentially life-threatening condition associated with increased serotonergic activity in the central nervous system. It is seen with therapeutic medication use, inadvertent interactions between drugs, and intentional self-poisoning. Serotonin syndrome may involve a spectrum of clinical findings, which often include mental status changes, autonomic hyperactivity, and neuromuscular abnormalities.
duration of the intervention (duration of invasive mechanical ventilation)
90-day survival
Tidsram: 90 days
Being alive at 90 days
90 days
Ventilator-Free Days
Tidsram: 28 days
Number of days alive and free of mechanical ventilation in the first 28 days with death before day 28 counted as 0
28 days
Coma-and-delirium-free days
Tidsram: 14 days
Number of days alive without delirium nor coma from any cause in the first 14 days
14 days

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Yiorgos Alexandros Cavayas, MD MSc, Centre Intégré Universitaire de Santé et Services Sociaux du Nord-de-l'Ile-de-Montréal - Hôpital du Sacré-Coeur de Montréal
  • Huvudutredare: David Williamson, BPharm, PhD, Centre Intégré Universitaire de Santé et Services Sociaux du Nord-de-l'Ile-de-Montréal - Hôpital du Sacré-Coeur de Montréal

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 oktober 2026

Primärt slutförande (Beräknad)

1 oktober 2028

Avslutad studie (Beräknad)

1 oktober 2029

Studieregistreringsdatum

Först inskickad

8 maj 2026

Först inskickad som uppfyllde QC-kriterierna

8 maj 2026

Första postat (Faktisk)

14 maj 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

14 maj 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

8 maj 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera